Search

Displaying results 2961 - 2970 of 8411 in total
  1. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  2. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a ...

  3. Drug

    Trinitrotoluene

    go.drugbank.com/drugs/DB01676
    Experimental

    Trinitrotoluene is an explosive chemical that can cause skin irritation and other toxic consequences.

  4. Drug

    Snail, unspecified

    go.drugbank.com/drugs/DB14245
    ApprovedInvestigational

    Snail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic com...

  6. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. . It was developed in the late 1980s out of ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  7. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  10. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    International brands: Scatron DMixtures: Regulex D Cap